Respiratory Syncytial Virus Vaccines Market To Reach $28.39 Billion By 2030

RSV Vaccines Market Growth & Trends

The global respiratory syncytial virusvaccines market size is expected to reach USD 28.39 billion by 2030, registering a CAGR of 42.17% from 2025 to 2030, according to a new report by Grand View Research, Inc. As populations age and comorbidities such as COPD, asthma, and diabetes become more prevalent, the demand for preventive measures like vaccination continues to rise. Regulatory approvals of RSV vaccines across multiple age groups have significantly expanded the addressable market. Furthermore, growing government support, including public immunization campaigns, has helped boost vaccination uptake and market penetration. The increasing global recognition of RSV as a serious public health threat underlines the importance of continued innovation and investment in this sector.

A key factor propelling market growth is the expansion of vaccine recommendations by public health authorities. In April 2025, the U.S. Advisory Committee on Immunization Practices (ACIP) voted to recommend RSV vaccines, including GSK’s AREXVY, for adults aged 50–59 who are at elevated risk of severe RSV disease. This includes individuals with chronic conditions such as asthma, chronic obstructive pulmonary disease (COPD), diabetes, heart disease, and those residing in long-term care facilities. This recommendation builds upon ACIP’s earlier vote in June 2024 to advise vaccination for all adults aged 75 and older, and for those aged 60–74 with underlying health risks. These policy expansions are critical in driving vaccine coverage and boosting the commercial viability of products like AREXVY, further energizing the RSV vaccine market.

Technological innovation and product differentiation are also vital forces shaping the RSV vaccine landscape. Breakthroughs in mRNA and adjuvanted vaccine platforms have improved efficacy, safety profiles, and delivery convenience. For example, Moderna’s mRESVIA, approved in May 2024 for adults aged 60 and older, represents the company’s second FDA-approved mRNA vaccine and highlights the momentum of mRNA technologies in infectious disease prevention. GSK’s AREXVY leverages an adjuvanted formulation to enhance immune response in older adults, especially those with weakened immune systems. The availability of multiple vaccine options tailored to different population segments supports competition while broadening access and boosting market confidence in RSV vaccine efficacy.

Increased investments from both public and private sectors are accelerating the pace of clinical trials and regulatory approvals. Major pharmaceutical companies such as Pfizer, Moderna, GSK, and Merck are actively pursuing new indications and age groups through extensive Phase 3 trials. Pfizer continues to expand its RSV vaccine ABRYSVO into younger adult age groups. These developments are expected to intensify competition, improve product innovation, and lower costs over time, which is crucial for sustaining long-term market growth, particularly in emerging economies.

Additionally, partnerships with global health organizations and tiered pricing strategies will be key in expanding RSV vaccine access across low- and middle-income countries. As climate change and global mobility contribute to changes in RSV seasonality and transmission patterns, integrated surveillance and responsive vaccination policies will be increasingly important. With expanding recommendations and a strong innovation pipeline, the RSV vaccine market is poised for continued growth and public health impact.

 Request a free sample copy or view report summary: Respiratory Syncytial Virus Vaccines Market Report

Respiratory Syncytial Virus Vaccines Market Report Highlights

• In 2024, passive immunization led the market with a market share of 75.02%, primarily driven by advancements in monoclonal antibody (mAb) therapies.

• The monoclonal antibodies (mAbs) segment secured the dominant market share in 2024. mAbs offer immediate passive immunity, making them ideal for protecting high-risk populations such as newborns and immunocompromised individuals.

• The infants and children held the largest market share of 75.02% in 2024, due to the high disease burden and recent preventive breakthroughs. RSV is the leading cause of hospitalization in infants globally, prompting urgent demand for effective protective measures.

• Hospital & retail pharmacies are expected to dominate the market in 2024 with share of 53.68% fueled by rising demand, vaccine accessibility, and expanding immunization programs.

• North America holds a substantial share of the global RSV vaccine market, attributed to the high prevalence of RSV infections and advanced healthcare infrastructure.

• The global RSV vaccines market is highly competitive, with key players such as AstraZeneca, Sanofi, GSK, Pfizer, Moderna, Icosavax, Meissa Vaccines, Codagenix, Blue Lake Biotechnology, and Merck, focusing on enhancing the vaccine.

Respiratory Syncytial Virus Vaccines Market Segmentation

Grand View Research has segmented the global RSV vaccines market report based on type, technology, targeted population, distribution channel, and region.

Respiratory Syncytial Virus Vaccines Type Outlook (Revenue, USD Million, 2018 - 2030)

• Passive Immunization

• Preventive Vaccines

Respiratory Syncytial Virus Vaccines Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Monoclonal Antibodies

• Recombinant Protein + Adjuvant

• mRNA-Based Vaccine

• Virus-Like Particle (VLP)

Respiratory Syncytial Virus Vaccines Targeted Population Outlook (Revenue, USD Million, 2018 - 2030)

• Adults

• Infants and children

Respiratory Syncytial Virus Vaccines Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital & Retail Pharmacies

• Government Suppliers

• Others

Respiratory Syncytial Virus Vaccines Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Respiratory Syncytial Virus Vaccines Market

• AstraZeneca

• Sanofi

• GSK

• Pfizer Inc.

• Moderna

• Icosavax

• Meissa Vaccines

• Codagenix

• Blue Lake Biotechnology

• Merck & Co., Inc.